Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
OREX [NASD]
Orexigen Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.34 Insider Own9.05% Shs Outstand123.73M Perf Week-2.39%
Market Cap910.65M Forward P/E- EPS next Y-0.36 Insider Trans-0.67% Shs Float122.82M Perf Month6.36%
Income-37.50M PEG- EPS next Q-0.14 Inst Own90.50% Short Float26.34% Perf Quarter36.04%
Sales55.50M P/S16.41 EPS this Y60.00% Inst Trans0.02% Short Ratio5.83 Perf Half Y70.37%
Book/sh0.18 P/B40.89 EPS next Y33.30% ROA-22.50% Target Price13.57 Perf Year33.09%
Cash/sh1.66 P/C4.43 EPS next 5Y20.00% ROE-247.50% 52W Range3.11 - 9.37 Perf YTD21.45%
Dividend- P/FCF34.24 EPS past 5Y28.10% ROI-28.80% 52W High-21.45% Beta2.44
Dividend %- Quick Ratio7.10 Sales past 5Y253.90% Gross Margin- 52W Low136.66% ATR0.40
Employees47 Current Ratio7.10 Sales Q/Q2577.90% Oper. Margin-55.00% RSI (14)49.05 Volatility6.66% 4.96%
OptionableYes Debt/Eq3.76 EPS Q/Q100.00% Profit Margin-67.60% Rel Volume0.42 Prev Close7.44
ShortableYes LT Debt/Eq3.76 EarningsMay 27 BMO Payout- Avg Volume5.55M Price7.36
Recom1.60 SMA20-4.80% SMA503.93% SMA20029.37% Volume2,337,035 Change-1.08%
Mar-27-15Reiterated RBC Capital Mkts Outperform $10 → $14
Jan-23-15Initiated RBC Capital Mkts Outperform $10
Jan-10-14Initiated WallachBeth Buy $9
Oct-03-13Initiated Cowen Outperform $10
Sep-21-11Upgrade JMP Securities Mkt Perform → Mkt Outperform $5
Feb-01-11Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-01-11Downgrade Canaccord Genuity Buy → Hold
Dec-03-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform
Jul-16-10Reiterated JMP Securities Mkt Outperform $16 → $13
Jul-16-10Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
Feb-02-10Initiated Jefferies & Co Buy $12
Jun-24-09Initiated Rodman & Renshaw Mkt Outperform $14
Mar-13-09Reiterated Lazard Capital Mkts Buy $13 → $10
Apr-03-08Initiated Cowen & Co Outperform
Feb-06-08Initiated Lazard Capital Buy
Feb-04-08Reiterated Canaccord Adams Buy $29 → $32
Jan-03-08Initiated JP Morgan Overweight
Oct-03-07Upgrade JMP Securities Mkt Outperform → Strong Buy $26
Jun-07-07Initiated JP Morgan Overweight
Jun-06-07Initiated JMP Securities Mkt Outperform $26
Apr-24-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX Marketwired
Apr-23-15 06:37PM  Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
05:44PM  TRADING ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of the Important May 11, 2015 Deadline in the Class Action Business Wire
04:06PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-22-15 07:41AM  Orexigen Announces Receipt of Paragraph IV Certification Notice at noodls
07:30AM  Orexigen Announces Receipt of Paragraph IV Certification Notice PR Newswire
Apr-21-15 10:39AM  SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Orexigen Therapeutics, Inc. and a Lead Plaintiff Deadline of May 11, 2015 Business Wire -5.03%
Apr-20-15 10:54AM  Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire
Apr-15-15 10:17AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 - OREX PR Newswire
Apr-14-15 05:02PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Apr-13-15 10:30AM  Law Offices of Howard G. Smith Reminds Investors of Orexigen Therapeutics, Inc. of the May 11, 2015 Deadline Business Wire
Apr-10-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Orexigen Therapeutics, Inc. Business Wire
04:39PM  Orexigen Therapeutics to Speak at the Needham Healthcare Conference at noodls
04:01PM  Orexigen Therapeutics to Speak at the Needham Healthcare Conference PR Newswire
01:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OREX PR Newswire
09:00AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 -- OREX GlobeNewswire
Apr-08-15 04:31PM  5 stocks to watch at MarketWatch
Apr-06-15 07:33PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Orexigen Therapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- OREX GlobeNewswire
Apr-03-15 12:42PM  EQUITY ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of Important Deadline in Class Action - OREX GlobeNewswire
Apr-02-15 07:14PM  DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Orexigen Therapeutics, Inc. Of Upcoming Deadline Business Wire
02:40PM  Vivus Goes on a Diet: Sales Reps are Cut, but Will FDA Help Save Money? at The Wall Street Journal
Mar-30-15 08:49AM  Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer at noodls
08:45AM  Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer PR Newswire
07:09AM  Leerink: Europe Deal Coming For Orexigen Therapeutics
Mar-27-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX GlobeNewswire
05:00PM  Barrack, Rodos & Bacine Has Filed an Investor Class Action Against Orexigen Therapeutics, Inc. GlobeNewswire
03:10PM  Orexigen's Obesity Drug Mysimba Gains European Approval - Analyst Blog
02:04PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Orexigen Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- OREX GlobeNewswire
11:23AM  Cohen Milstein Sellers & Toll PLLC Announces the Investigation of Orexigen Therapeutics, Inc. GlobeNewswire
10:25AM  U.S. stocks on track for big weekly loss at MarketWatch
08:25AM  Ahead of the Bell: Orexigen shares rise
Mar-26-15 08:54PM  Oxford Industries, Orexigen And GameStop Lead Thursday's After-Hours Movers
04:32PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events
03:13PM  Orexigen gets approval to market weight loss drug in Europe
02:22PM  Orexigen's Mysimba Approved in Europe for the Treatment of Obesity PR Newswire
Mar-25-15 01:17PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX GlobeNewswire
11:54AM  OREX Shareholder Alert: Investigation on Behalf of Orexigen Therapeutics, Inc. Investors Announced by Law Offices of Howard G. Smith Business Wire
Mar-24-15 09:35AM  Deadline in Lawsuit for Investors in Orexigen Therapeutics, Inc. (NASDAQ:OREX) Shares Announced by Shareholders Foundation GlobeNewswire
Mar-23-15 11:30AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Orexigen Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Mar-20-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. Business Wire -5.39%
09:45PM  IMPORTANT ANNOUNCEMENT: Wolf Haldenstein Adler Freeman & Herz LLP Announces That a Federal Securities Class Action Has Been Filed Against Orexigen Therapeutics, Inc. GlobeNewswire
Mar-18-15 04:54PM  Can Orexigen Win Where Obesity-Drug Rivals Failed? at Investopedia
09:30AM  Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releases
Mar-16-15 02:10PM  INVESTOR ALERT: Investigation of Orexigen Therapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP Business Wire
09:54AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX Marketwired
09:11AM  Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire
Mar-14-15 07:37PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Orexigen Therapeutics, Inc. (OREX) to Contact the Firm Marketwired
05:00AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Orexigen Therapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- OREX GlobeNewswire
Mar-12-15 06:53PM  Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Orexigen Therapeutics, Inc. PR Newswire
11:19AM  Investor Class Action Filed by Barrack, Rodos & Bacine Against Orexigen Therapeutics, Inc. ("OREX") GlobeNewswire
Mar-11-15 10:00PM  OREXIGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Orexigen Therapeutics, Inc. -- OREX GlobeNewswire -5.07%
07:30PM  Harwood Feffer LLP Announces Investigation of Orexigen Therapeutics, Inc. PR Newswire
05:26PM  Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Orexigen Therapeutics, Inc. Stockholders Business Wire
02:27PM  EQUITY ALERT: The Rosen Law Firm Announces the Filing of a Securities Class Action Against Orexigen Therapeutics, Inc. Seeking to Recover Investor Losses - OREX Business Wire
02:08PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Orexigen Therapeutics, Inc. and Certain Officers -- OREX GlobeNewswire
12:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of OREXIGEN THERAPEUTICS, INC. of PENDENCY OF CLASS ACTION Lawsuit and a Lead Plaintiff DEADLINE of May 11, 2015 -- OREX GlobeNewswire
11:52AM  Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Orexigen Therapeutics, Inc. PR Newswire
Mar-10-15 10:00PM  Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Orexigen Therapeutics, Inc. Business Wire
12:10AM  Did Orexigen Make A Big Mistake? at Investopedia
Mar-09-15 05:06PM  Novo Nordisk's Saxenda: New Data from Phase IIIa Study - Analyst Blog Zacks
01:46PM  Nasdaq stocks posting largest percentage decreases AP
10:16AM  What Should FDA do About the Orexigen Data Disclosure? Take our Poll at The Wall Street Journal
Mar-06-15 11:01PM  OREXIGEN SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Orexigen Therapeutics, Inc. Business Wire -11.36%
03:44PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Orexigen Therapeutics, Inc. Business Wire
02:56PM  Analyst: FDA Won't Pull Permit On Orexigen Therapeutics Benzinga
11:39AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orexigen Therapeutics, Inc. - OREX PR Newswire
10:02AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orexigen Therapeutics, Inc. PR Newswire
08:52AM  Ahead of the Bell: Orexigen Therapeutics shares retreat AP
Mar-05-15 05:55PM  Orexigen falls after hours CNBC -5.65%
05:28PM  Top FDA Official Says Orexigen Study Result 'Unreliable,' 'Misleading' at Forbes
02:02PM  Orexigen 'Crying All The Way To The Bank' After 'Egregiously Unethical' Actions at Forbes
01:29PM  Nasdaq stocks posting largest percentage increases AP
11:27AM  Takeda Disagrees With Orexigen Over Data Disclosure at Forbes
10:23AM  Kroger gains on higher profit; AbbVie slides on merger news at MarketWatch
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Gilead, Celgene and Orexigen - Press Releases Zacks
Mar-04-15 06:18PM  Nasdaq stocks posting largest volume increases AP +11.13%
05:30PM  Orexigen soars on drug data CNBC
04:45PM  Orexigen Soars as Interim Data on Contrave Comes to Light - Analyst Blog Zacks
03:05PM  Orexigen Therapeutics (OREX) Stock Surging Today on Heavy Volume at TheStreet
01:28PM  Wednesday's Mid-Day Movers: PhotoMedex, Career Education And More Benzinga
11:35AM  Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog Zacks
10:57AM  Fat Chance: FDA Chastises Orexigen for Disclosing Interim Trial Data at The Wall Street Journal
Mar-03-15 09:07PM  Report: Orexigen Therapeutics Jumped Gun On Contrave Heart Study Benzinga +31.95%
04:44PM  Orexigen Jumps on Diet Pills Heart Benefit as FDA Frowns at Bloomberg
04:44PM  Best Buy and Orexigen are big market movers AP
04:13PM  Orexigen Comments On Data Disclosure That "Disappointed" FDA at Forbes
03:36PM  Nasdaq backs off from 5,000 CNBC
03:33PM  The FDA Is Forcing Orexigen To Do A Second Safety Study Because Of Contrave Disclosures at Forbes
02:16PM  Has Orexigen Endangered Its Future To Boost Its Stock? at Forbes
02:06PM  Orexigen Released Interim Data Without Approval Of Trial Leaders at Forbes
01:54PM  Orexigen Soars On Obesity Drug's Surprise Health Boon at Investor's Business Daily
11:51AM  Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit at TheStreet
Mar-02-15 06:05PM  What Are The Real Economic Costs Of Obesity? at Investopedia
Feb-27-15 03:08PM  OREXIGEN THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
Feb-26-15 09:30AM  Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Zacks
Feb-25-15 07:30AM  Orexigen Therapeutics Inc Earnings Call scheduled for 7:30 am ET today CCBN
07:07AM  Q4 2014 Orexigen Therapeutics Inc Earnings Release - Before Market Open CCBN
06:45AM  Orexigen misses 4Q profit forecasts AP
06:42AM  OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
06:30AM  Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014 PR Newswire
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Booth Mark DChief Commercial OfficerFeb 26Option Exercise1.6650,00083,00053,810Mar 02 05:34 PM
Booth Mark DChief Commercial OfficerFeb 26Sale5.6850,000284,2003,810Mar 02 05:34 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Option Exercise1.6622,64337,58722,643Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryDec 02Sale6.0022,643135,8580Dec 04 05:05 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Option Exercise1.667,38212,2547,382Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 25Sale6.007,38244,2920Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Option Exercise1.6624,00639,85024,006Nov 26 05:01 PM
Turner Heather DSVP, Gen. Counsel & SecretaryNov 24Sale5.7724,006138,5870Nov 26 05:01 PM
BOCK LOUIS CDirectorNov 18Buy5.587003,905700Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 18Buy5.586253,48727,677Nov 20 09:16 AM
BOCK LOUIS CDirectorNov 12Buy5.5727,052150,54427,052Nov 13 09:27 AM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Option Exercise1.66300,000498,000300,000Sep 22 06:49 PM
Turner Heather DVP, Gen. Counsel & SecretarySep 22Sale4.47300,0001,339,5000Sep 22 06:49 PM
Hagan Joseph PSr. VP, Corporate DevelopmentSep 15Buy4.695,00023,45013,026Sep 15 03:11 PM
NARACHI MICHAELPresident and CEOSep 15Buy4.7850,000239,10058,026Sep 15 02:41 PM